StreetInsider.com News Articles

Form 6-K IceCure Medical Ltd. For: Jun 18

Thu, 18 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260618/26666820.html

Form 6-K IceCure Medical Ltd. For: Jun 18

Thu, 18 Jun 2026 16:47:00 -0400

si-local-file:///var/storage/secattach/20260618/26666820.html

IceCure Medical prices $5.5 million private placement at $3.00 per share

Wed, 17 Jun 2026 13:15:20 -0400

IceCure Medical Ltd. (Nasdaq: ICCM) has entered into securities purchase agreements with a single healthcare-focused institutional investor for a private placement expected to raise approximately $5.5 million in gross proceeds, before placement agent commissions and other expenses.

The offering includes 1,833,334 ordinary shares, Series D Warrants to purchase up to 1,833,334 ordinary shares, and Series E Warrants to purchase up to 1,833,334 ordinary shares, all at a combined purchase price of $3.00 per share. The company said the price represents a premium to the previous Nasdaq closing price of its ordinary shares.

Both warrant series carry an exercise price of $3.00 per

IceCure Medical prices $5.5 million private placement at $3.00 per share

Wed, 17 Jun 2026 13:15:20 -0400

Both warrant series carry an exercise price of $3.00 per

IceCure Medical prices $5.5 million private placement at $3.00 per share

Wed, 17 Jun 2026 13:15:20 -0400

Both warrant series carry an exercise price of $3.00 per

IceCure Medical prices $5.5 million private placement at $3.00 per share

Wed, 17 Jun 2026 13:15:20 -0400

Both warrant series carry an exercise price of $3.00 per

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Wed, 17 Jun 2026 13:14:00 -0400

CAESAREA, Israel, June 17, 2026 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure", "IceCure Medical" or the "Company"), developer of minimally-invasive cryoablation technology that destroys tumors by freezing as an option to surgical tumor removal, today announced that it has entered into securities purchase agreements with a single healthcare focused institutional investor, for the purchase and sale of 1,833,334 ordinary shares (or ordinary share equivalents in lieu thereof), Series D Warrants to purchase up to 1,833,334 ordinary shares (the "Series D Warrants") and Series E Warrants to purchase

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Wed, 17 Jun 2026 13:14:00 -0400

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Wed, 17 Jun 2026 13:14:00 -0400

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Wed, 17 Jun 2026 13:14:00 -0400

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Wed, 17 Jun 2026 13:14:00 -0400

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Wed, 17 Jun 2026 13:14:00 -0400

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Wed, 17 Jun 2026 13:14:00 -0400

IceCure Announces Pricing of $5.5 Million Private Placement Priced At a Premium to the Market Price with a Single Healthcare Focused Institutional Investor

Wed, 17 Jun 2026 13:14:00 -0400

Biotech's New Frontier: Companies Breaking Through Medicine's Toughest Barriers

Wed, 17 Jun 2026 10:37:33 -0400